In Vitro Studies of Ciprofloxacin and Survey of Resistance Patterns in Current Isolates
Overview
Microbiology
Pathology
Authors
Affiliations
We studied the activity of ciprofloxacin and other antibiotics against both routine and multiresistant (multi-R) clinical isolates. Ciprofloxacin inhibited more than 98% of most species of Enterobacteriaceae at a concentration of 2 micrograms/ml. Only Acinetobacter calcoaceticus, and to a much lesser degree, Providencia and Serratia, were resistant. Most Pseudomonas aeruginosa isolates were susceptible. Only 1% of staphylococci were resistant; the test panel included 1200 MRSA. For most species of streptococci, the MIC90 was 1 microgram/ml; for enterococci, it was 2 micrograms/ml. We also surveyed resistance in our current isolates. Resistance to ciprofloxacin has increased in A. calcoaceticus and Providencia, and in Streptococcus pneumoniae and group B streptococci. Ciprofloxacin-resistant isolates tended to show increased resistance to other antibiotics, including aminoglycosides and, later, cephalosporins.
Fluoroquinolone Therapy in Staphylococcus aureus Infections: Where Do We Stand?.
Gade N, Qazi M J Lab Physicians. 2014; 5(2):109-12.
PMID: 24701103 PMC: 3968619. DOI: 10.4103/0974-2727.119862.
Janoir C, Zeller V, Kitzis M, Moreau N, Gutmann L Antimicrob Agents Chemother. 1996; 40(12):2760-4.
PMID: 9124836 PMC: 163617. DOI: 10.1128/AAC.40.12.2760.
Fuchs P, Barry A, Brown S J Clin Microbiol. 1997; 35(1):125-31.
PMID: 8968893 PMC: 229524. DOI: 10.1128/jcm.35.1.125-131.1997.
Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.
Davis R, Markham A, Balfour J Drugs. 1996; 51(6):1019-74.
PMID: 8736621 DOI: 10.2165/00003495-199651060-00010.
Penetration of ciprofloxacin into the human pancreas.
Isenmann R, Friess H, Schlegel P, Fleischer K, Buchler M Infection. 1994; 22(5):343-6.
PMID: 7843813 DOI: 10.1007/BF01715543.